To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.

Back to Search
Print
Bookmark Trial

NCT00141375

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Little Bay, New South Wales, 2036, Australia
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neuropathic Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury.

- Must have received study medication under double-blind conditions.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients cannot participate if they experienced a serious adverse event during the
previous double-blind BID study which was determined to be related to the study
medication.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Neuropathic PainA Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain NCT00301223
  1. Beijing,
  2. Cheng Du Si Chaun,
  3. Guang Zhou,
  4. Nan Jing, Jiang Su,
  5. Qing Dao Shan Dong,
  6. Shang Hai,
  7. Shanghai,
  8. Tian Jin,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Neuropathic PainEfficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain. NCT00219544
  1. Calgary, Alberta
  2. Calgary, Alberta
  3. Calgary, Alberta
  4. Edmonton, Alberta
  5. Edmonton, Alberta
  6. Red Deer, Alberta
  7. Kelowna, British Columbia
  8. Vancouver, British Columbia
  9. Vancouver, British Columbia
  10. Winnipeg, Manitoba
  11. Winnipeg, Manitoba
  12. Winnipeg, Manitoba
  13. Halifax, Nova Scotia
  14. Kingston, Ontario
  15. London, Ontario
  16. Port Hope, Ontario
  17. Toronto, Ontario
  18. Charlottetown, Prince Edward Island
  19. Granby, Quebec
  20. Laval, Quebec
  21. Laval, Quebec
  22. Levis, Quebec
  23. Mirabel, Quebec
  24. Montreal, Quebec
  25. Montreal, Quebec
  26. Montreal, Quebec
  27. Sherbrooke, Quebec
  28. Sherbrook, Quebec
  29. Ste-Foy, Quebec
  30. Saskatoon, Saskatchewan
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Neuropathic PainA Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin NCT00892008
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Neuropathic PainTo Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury. NCT00141375
  1. Little Bay, New South Wales
  2. St. Leonards, New South Wales
  3. Warrawong, New South Wales
  4. Woolloongabba, Queensland
  5. Heidelberg, Victoria
  6. Shenton Park, Western Australia
  7. NSW,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.
Official Title  ICMJE An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury.
Brief Summary To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Neuropathic Pain
Intervention  ICMJE Drug: Pregabalin
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: August 31, 2005)		132
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE January 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury.
  • Must have received study medication under double-blind conditions.

Exclusion Criteria:

  • Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00141375
Other Study ID Numbers  ICMJE 1008-000-202
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP